Recombinant Rat Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (Rpn1)

What is Rpn1 and what is its primary function?

Rpn1 (Ribophorin I) is a subunit of the oligosaccharyltransferase complex that plays a crucial role in facilitating N-glycosylation of proteins. This post-translational modification process is fundamental to numerous biological functions, including protein folding, stability, and cellular signaling. Rpn1 specifically contributes to the transfer of oligosaccharide chains from dolichol pyrophosphate donors to asparagine residues in nascent polypeptide chains within the endoplasmic reticulum. Studies in knockout models demonstrate that Rpn1 is indispensable for proper protein N-linked glycosylation, as its deletion results in severe defects in this modification pathway .

What experimental models are commonly used to study Rpn1 function?

Researchers typically employ conditional knockout mouse models to study Rpn1 function in specific tissues or developmental contexts. The generation of Rpn1 flox/flox mice using CRISPR-Cas9 gene editing technology has been documented, with subsequent breeding to tissue-specific Cre recombinase-expressing lines such as Vasa-Cre and Stra8-GFPCre to achieve germ cell-specific deletion. These models allow for the investigation of Rpn1's role in specific cellular processes without the complications of embryonic lethality that might result from global deletion. Cell culture systems using CRISPR/Cas9 for Rpn1 knockout have also been employed to study its function in cancer cells and other contexts .

How are recombinant Rpn1 proteins produced for research purposes?

Recombinant Rpn1 proteins are typically produced using eukaryotic expression systems, similar to other glycoproteins. While the search results don't specifically detail Rpn1 production methods, related glycoproteins like GDNF are produced in insect cell systems such as Spodoptera frugiperda (Sf21) with baculovirus vectors. For Rpn1, expression systems that maintain proper glycosylation capabilities would be essential. Purification typically involves affinity chromatography techniques such as Nickel IMAC chromatography when His-tags are incorporated. The purified protein is commonly formulated in phosphate-buffered saline (pH 7.4) and stored at -20°C with precautions to avoid repeated freeze-thaw cycles .

What are the structural characteristics and modifications of Rpn1?

Rpn1 contains N-glycosylation motifs that are critical for its function and stability. In recombinant production, these sites may require special consideration. For example, in some recombinant proteins, N-glycosylation motifs may be mutated to avoid hyper-glycosylation (as noted in the N35Q mutation in a related recombinant protein). Typically, recombinant versions include purification tags such as a C-terminal 6xHis-tag to facilitate isolation. The molecular weight of the rat Rpn1 is approximately 68 kDa, though this can vary depending on post-translational modifications, particularly glycosylation states. When analyzing recombinant Rpn1 by techniques such as SDS-PAGE, both reducing and non-reducing conditions may reveal different molecular weights due to the potential formation of disulfide bonds .

What are the consequences of Rpn1 knockout in specific tissues?

Germ cell-specific Rpn1 knockout in male mice results in profound reproductive defects. The deletion of Rpn1 significantly inhibits meiotic progression, disrupting critical processes including homologous chromosome pairing, meiotic recombination, and DNA double-strand break repair. N-glycoproteomic profiling of Rpn1 knockout testes revealed reduced glycosylation levels in endoplasmic reticulum-associated proteins. Functional analyses demonstrated that Rpn1 deficiency inhibits endoplasmic reticulum function and triggers endoplasmic reticulum stress during meiosis, ultimately increasing apoptosis levels in mice. These findings highlight the essential physiological role of N-glycosylation modification mediated by Rpn1 in male spermatogenesis and fertility .

How can N-glycoproteomics be used to study Rpn1-dependent glycosylation?

TMT-based quantitative proteomics and N-glycoproteomics analyses provide powerful tools for quantifying differences in proteins and N-glycosylation patterns between wild-type and Rpn1 knockout tissues. This approach involves:

• Sample preparation: Harvesting tissues (e.g., PD12 testes) from wild-type and Rpn1 knockout mice

• Protein extraction and digestion

• TMT labeling of peptides

• Enrichment of glycopeptides

• LC-MS/MS analysis

• Data processing and statistical analysis

This methodology identified 50 N-glycopeptides with significant changes in Rpn1 knockout mice compared to controls (|FC| >1.5; p-value< 0.05), including 15 glycopeptides from 10 glycoproteins with increased abundance and 35 glycopeptides from 27 glycoproteins with decreased abundance. Subsequent Gene Ontology (GO) and KEGG pathway analyses revealed enrichment in biological processes such as "endoplasmic reticulum to Golgi vesicle-mediated transport," "protein folding," and "cell morphogenesis" .

What is the relationship between Rpn1 and endoplasmic reticulum stress?

Rpn1 deletion triggers endoplasmic reticulum stress (ERS) and causes endoplasmic reticulum dysfunction. N-glycoproteomics analysis identified seven glycoproteins with decreased glycosylation in Rpn1 knockout tissues that were related to the unfolded protein response (UPR) and ERS. Western blot analyses of ERS-related glycoproteins in wild-type and Rpn1 knockout testes, with or without treatment with the recombinant glycosidase PNGase F, demonstrated that these proteins are heavily glycosylated in normal testes. The molecular weight shift observed after PNGase F treatment in wild-type samples was absent in Rpn1 knockout tissues, suggesting that Rpn1 mediates specific glycosylation modifications on these proteins rather than all glycosylation sites. This mechanism provides insight into how Rpn1 deficiency leads to ERS, as proper glycosylation of ER chaperone proteins is essential for their function in protein folding and quality control .

What is the role of Rpn1 in cancer biology and as a potential biomarker?

Rpn1 has emerged as a pan-cancer biomarker and disulfidptosis regulator. Through genome-wide CRISPR/Cas9 screening, Rpn1 was identified as a key gene contributing to disulfidptosis, a cell death mechanism triggered by cysteine deprivation. Rpn1 promotes disulfidptosis by inducing cell skeleton protein breakdown. Research indicates that Rpn1 serves as a significant biomarker across diverse cancer types and correlates with the efficacy of immune therapy targeting PD-L1, particularly in urothelial carcinoma. Knockout of the Rpn1 gene inhibits disulfidptosis in various cell lines, regardless of SLC7A11 expression levels, suggesting Rpn1 as a potential universal target for cancer therapy .

How can Rpn1 function be validated experimentally?

To validate Rpn1 function experimentally, researchers can employ multiple complementary approaches:

Verification of Rpn1's role in N-glycosylation can be accomplished by comparing glycosylation levels in wild-type and knockout samples using lectins such as Con A. PNGase F treatment, which removes N-linked oligosaccharides from polypeptides, can be used to confirm the glycosylation status of specific proteins. The absence of molecular weight shifts after PNGase F treatment in Rpn1 knockout samples compared to wild-type would indicate reduced glycosylation .

What are the best practices for preparing recombinant Rpn1 for experimental use?

When working with recombinant Rpn1, researchers should consider the following best practices:

• Storage: Store at -20°C and avoid repeated freeze-thaw cycles to maintain protein integrity.

• Formulation: Use preservative-free and carrier-free buffers such as phosphate-buffered saline (pH 7.4) with sterile filtration.

• Quality control: Verify purity using silver-stained SDS-PAGE (expecting >95% purity).

• Functional validation: Confirm biological activity through appropriate functional assays relevant to Rpn1's role in N-glycosylation.

• Concentration determination: Use validated protein quantification methods and include detailed specifications in product documentation.

• Glycosylation status assessment: Consider the native glycosylation pattern and any modifications made during recombinant production, such as mutations to prevent hyper-glycosylation .

How can researchers analyze N-glycosylation changes in Rpn1 knockout models?

Researchers can analyze N-glycosylation changes in Rpn1 knockout models through several approaches:

• TMT-based quantitative proteomics and N-glycoproteomics: This comprehensive approach allows for the identification and quantification of differentially glycosylated proteins between wild-type and knockout samples.

• Lectin-binding assays: Lectins such as concanavalin A (Con A) selectively bind to specific glycan structures, allowing for the detection and comparison of glycosylation levels between samples.

• Western blot analysis with PNGase F treatment: Treatment of protein samples with PNGase F removes N-linked oligosaccharides, resulting in a shift to lower molecular weights for glycosylated proteins. Comparing the molecular weight shifts between wild-type and knockout samples can indicate differences in glycosylation status.

• GO and KEGG pathway enrichment analysis: These bioinformatic approaches help identify biological processes and pathways affected by changes in protein glycosylation.

• Sankey diagrams: These can be used to visualize the relationships between differentially glycosylated proteins and their associated biological processes or cellular components .

What are the critical factors to consider when designing experiments involving Rpn1?

When designing experiments involving Rpn1, researchers should consider:

• Model system selection: Choose appropriate in vitro or in vivo models based on research questions, considering that Rpn1 function may vary across tissues and developmental stages.

• Conditional vs. complete knockout: Global deletion of Rpn1 may be lethal, necessitating tissue-specific or inducible knockout approaches using appropriate Cre-lox systems.

• Temporal considerations: Select appropriate time points for analysis, especially in developmental studies (e.g., PD12 for early meiotic processes in testis).

• Control and validation strategies: Include proper controls and validation methods to confirm Rpn1 knockout efficiency and specificity.

• Downstream pathway analysis: Consider the broader impact of Rpn1 knockout on related biological processes, including endoplasmic reticulum stress, protein folding, and cell morphogenesis.

• Glycoprotein target identification: Use appropriate methods to identify specific glycoproteins affected by Rpn1 deletion, focusing on those relevant to the pathway or process under investigation .

How is Rpn1 being investigated as a potential therapeutic target in cancer?

Rpn1 has emerged as a promising therapeutic target in cancer research due to its role in disulfidptosis regulation and its significance as a pan-cancer biomarker. Studies have demonstrated that inhibition of Rpn1 can affect disulfidptosis in cancer cells, regardless of SLC7A11 expression levels. This suggests that Rpn1 could serve as a universal target for cancer therapy. Additionally, Rpn1 expression correlates with the efficacy of immune checkpoint inhibitor therapy targeting PD-L1, particularly in urothelial carcinoma. These findings suggest multiple potential therapeutic approaches:

• Direct inhibition of Rpn1 to induce disulfidptosis in cancer cells

• Combination therapy with immune checkpoint inhibitors based on Rpn1 expression levels

• Development of biomarkers based on Rpn1 expression to predict treatment response

Further research is needed to explore whether other metabolic stress conditions can lower intracellular NADPH levels, thus inducing disulfidptosis, and to validate Rpn1's role as an immune therapy marker in larger cohorts .

What is the relationship between Rpn1, N-glycosylation, and cell death mechanisms?

The relationship between Rpn1, N-glycosylation, and cell death mechanisms represents a complex interplay of cellular processes. Rpn1, as a key component of the oligosaccharyltransferase complex, facilitates N-glycosylation of proteins, many of which are involved in endoplasmic reticulum function and stress response. Disruption of Rpn1-mediated glycosylation can lead to:

• Endoplasmic reticulum stress: Improper glycosylation of ER chaperone proteins impairs their function in protein folding and quality control, triggering the unfolded protein response.

• Increased apoptosis: Studies in Rpn1 knockout mice have demonstrated elevated levels of apoptosis, particularly during meiosis in spermatogenesis.

• Disulfidptosis regulation: Rpn1 promotes disulfidptosis, a cell death mechanism triggered by cysteine deprivation, through inducing cell skeleton protein breakdown.

These findings suggest that Rpn1's role in N-glycosylation is integral to cellular homeostasis and that its dysregulation can contribute to various cell death pathways. Understanding these relationships could lead to novel therapeutic approaches targeting specific cell death mechanisms in diseases such as cancer .

How does Rpn1 function differ across species and tissues?

While the search results primarily focus on rat and mouse Rpn1, there are indications that Rpn1 function may vary across species and tissues. In Arabidopsis, Rpn1 plays a crucial role in innate immunity, suggesting evolutionary conservation of some functions with potential divergence in others. Within mammals, Rpn1's critical role in spermatogenesis has been well-documented, but its functions in other tissues and developmental processes are still being elucidated. The conditional knockout approach using tissue-specific Cre recombinase expression provides a valuable tool for investigating these tissue-specific functions. Future research directions could include comparative studies of Rpn1 function across different tissues and species to identify conserved and divergent roles of this important protein in N-glycosylation and beyond .

What are common challenges in working with recombinant Rpn1 and how can they be addressed?

Researchers working with recombinant Rpn1 may encounter several challenges:

• Maintaining glycosylation fidelity: Since Rpn1 is naturally glycosylated, expression systems must be selected carefully to ensure proper post-translational modifications. Eukaryotic expression systems like insect cells or mammalian cells are preferred over bacterial systems.

• Protein solubility and stability: As a membrane-associated protein, Rpn1 may have solubility issues. Using appropriate detergents during purification and formulation in buffers that maintain protein stability is essential.

• Functional activity assessment: Developing reliable assays to verify the functional activity of recombinant Rpn1 in N-glycosylation can be challenging. Enzymatic assays or binding studies with other components of the oligosaccharyltransferase complex may be useful.

• Avoiding aggregation: Proper storage conditions (-20°C) and minimizing freeze-thaw cycles are crucial to prevent protein aggregation and maintain functionality.

• Controlling glycosylation: Strategic mutation of specific N-glycosylation sites (e.g., N35Q) may be necessary to prevent hyper-glycosylation in some expression systems .

How can researchers optimize N-glycoproteomics protocols for studying Rpn1 targets?

Optimizing N-glycoproteomics protocols for studying Rpn1 targets requires attention to several key aspects:

• Sample preparation: Careful tissue or cell harvesting at appropriate developmental stages (e.g., PD12 for meiotic studies in testes).

• Protein extraction and digestion: Use of appropriate buffers and proteases that maximize protein coverage while maintaining glycopeptide integrity.

• Glycopeptide enrichment: Optimization of enrichment protocols using lectins or hydrazide chemistry to capture glycopeptides efficiently.

• Mass spectrometry settings: Adjustment of fragmentation parameters to preserve glycan structures while obtaining peptide sequence information.

• Data analysis pipeline: Implementation of appropriate software tools for glycopeptide identification and quantification, with statistical methods for identifying significant changes.

• Validation strategies: Confirmation of key findings using orthogonal methods such as western blotting with PNGase F treatment or lectin binding assays.